首页> 外文期刊>Hepato-gastroenterology. >The effect of polysaccharide K with S-1 based chemotherapy in advanced gastric cancer
【24h】

The effect of polysaccharide K with S-1 based chemotherapy in advanced gastric cancer

机译:多糖K联合S-1化疗在晚期胃癌中的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aims: Polysaccharide K (PSK) is widely used in Japan as a biological response modifier for cancer patients. We investigated the effects of PSK with S-1 based chemotherapy for advanced gastric cancer patients in immune response. Methodology: Nine advanced gastric cancer patients who underwent chemotherapy at the University of Tokushima were included in this study. In all patients, 3g PSK was received orally and S-1 based chemotherapy for 2 weeks alternately for 8 weeks. Serial changes in immunological parameters (Foxp3, Natural killer (NK), CD4/CD8) were monitored. Results: The levels of Foxp3 at 8 weeks was significantly decreased compared with 2 weeks (4.26% vs. 3.11%). In NK activity at 8 weeks was significantly increased compared with 2 weeks (27% vs. 47%). Conclusions: These results of this study suggested that chemotherapy with PSK improved the immune response in advanced gastric cancer patients. Especially Foxp3 was concerned in this mechanism.
机译:背景/目的:多糖K(PSK)在日本被广泛用作癌症患者的生物反应调节剂。我们调查了基于S-1的PSK化疗对晚期胃癌患者免疫应答的影响。方法:本研究包括9名在德岛大学接受化疗的晚期胃癌患者。在所有患者中,口服3g PSK和基于S-1的化学疗法,连续2周,持续8周。监测免疫学参数(Foxp3,自然杀手(NK),CD4 / CD8)的连续变化。结果:与2周相比,在8周时Foxp3的水平显着降低(4.26%对3.11%)。与2周相比,第8周的NK活性显着提高(27%比47%)。结论:本研究的这些结果表明,PSK化疗可改善晚期胃癌患者的免疫反应。特别是Foxp3担心这种机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号